Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls

Markéta Paclíková; Lukáš Konečný; Alejandro Carazo; Kateřina Matoušová; Lenka Kujovská Krčmová; V. Bláha; Alena Šmahelová; Přemysl Mladěnka

doi:10.1186/s12933-025-02891-6

August 7, 2025Cardiovascular DiabetologyOpen Access

Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls

View Full Paper

Ask AI

Bookmark

Share

Key Points

Type 1 diabetes patients showed reduced platelet aggregation compared to healthy controls.
Patients were more resistant to acetylsalicylic acid and vorapaxar than the control group.
4-methylcatechol emerged as a more potent antiplatelet agent in type 1 diabetes.
Plasma glucose levels above 7 mM correlated with lower response to platelet aggregation inducers.],
simple_explanation
In type 1 diabetes, certain medications that usually help with blood platelets may not work as well. For example, acetylsalicylic acid and vorapaxar were less effective in these patients. However, a new compound called 4-methylcatechol actually worked better than expected. This is important because it might help improve treatments for people with type 1 diabetes who need better blood flow. 🌟
} } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } }}

Implication

Research shows altered platelet response to acetylsalicylic acid and vorapaxar in type 1 diabetes, indicating 4-methylcatechol may be more effective.

Abstract

Introduction It is well known that platelets from diabetic patients can be resistant to clinically used antiplatelet drugs. Methods To assess the phenomenon in more detail, 50 adult patients suffering from type 1 diabetes mellitus (T1D) were recruited and their responses to 7 platelet aggregation inducers, as well as to 3 clinically used antiplatelet drugs (acetylsalicylic acid /ASA/, ticagrelor and vorapaxar) and one experimental compound, 4-methylcatechol, were assessed ex vivo. A control group of 50 generally healthy age-matched controls was also included for comparison. Results T1D patients exhibited a lower aggregation reaction to 3 inducers but were conversely more resistant to the effect of ASA and vorapaxar than controls. Ticagrelor tended to be less active in T1D as well. On the other hand, 4-methylcatechol was equally or even more potent in T1D than in healthy controls. Plasma glucose levels above 7 mM were associated with lower platelet aggregation responses to four aggregation inducers. In contrast, the effect of 4-methylcatechol, unlike that of ASA, did not appear to be strongly influenced by glycemia. Further subanalyses, excluding hypertensive patients and significantly more frequently administered drugs, did not substantially modify the results. Conclusion Conclusively, 4-methylcatechol seems to be a prototypical antiplatelet compound with a strong effect even in diabetic patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Paclíková et al. (2025) studied this question.

synapsesocial.com/papers/689dfe9fd61984b91e13c2fd https://doi.org/10.1186/s12933-025-02891-6

View Full Paper

Ask AI

Bookmark

Share

Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls

Key Points

Implication

Abstract

Discussion

Cite This Study

Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading